MX2011011957A - Composicion farmaceutica libre de fosfatos para el tratamiento del glaucoma. - Google Patents

Composicion farmaceutica libre de fosfatos para el tratamiento del glaucoma.

Info

Publication number
MX2011011957A
MX2011011957A MX2011011957A MX2011011957A MX2011011957A MX 2011011957 A MX2011011957 A MX 2011011957A MX 2011011957 A MX2011011957 A MX 2011011957A MX 2011011957 A MX2011011957 A MX 2011011957A MX 2011011957 A MX2011011957 A MX 2011011957A
Authority
MX
Mexico
Prior art keywords
phosphate
pharmaceutical composition
glaucoma
treatment
free pharmaceutical
Prior art date
Application number
MX2011011957A
Other languages
English (en)
Inventor
Frank Holzer
Original Assignee
Ursapharm Arzneimittel Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42556688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011011957(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ursapharm Arzneimittel Gmbh filed Critical Ursapharm Arzneimittel Gmbh
Publication of MX2011011957A publication Critical patent/MX2011011957A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se relaciona con una composición farmacéutica libre de fosfatos la cual comprende por lo menos un agonista del receptor prostanoide FP y/o por lo menos un agonista del receptor de prostamida y sales de citrato y /o ácido cítrico.
MX2011011957A 2009-05-14 2010-05-14 Composicion farmaceutica libre de fosfatos para el tratamiento del glaucoma. MX2011011957A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009021372A DE102009021372A1 (de) 2009-05-14 2009-05-14 Phosphatfreie pharmazeutische Zusammensetzung zur Glaukombehandlung
PCT/EP2010/002981 WO2010130462A2 (de) 2009-05-14 2010-05-14 Phosphatfreie pharmazeutische zusammensetzung zur glaukombehandlung

Publications (1)

Publication Number Publication Date
MX2011011957A true MX2011011957A (es) 2011-12-06

Family

ID=42556688

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011957A MX2011011957A (es) 2009-05-14 2010-05-14 Composicion farmaceutica libre de fosfatos para el tratamiento del glaucoma.

Country Status (11)

Country Link
US (1) US20120122976A1 (es)
EP (1) EP2429507B1 (es)
KR (1) KR20120047851A (es)
CN (1) CN102421425A (es)
DE (1) DE102009021372A1 (es)
ES (1) ES2644218T3 (es)
MX (1) MX2011011957A (es)
PL (1) PL2429507T3 (es)
PT (1) PT2429507T (es)
RU (1) RU2011143860A (es)
WO (1) WO2010130462A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2567689A1 (en) * 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US20140378401A1 (en) * 2013-06-21 2014-12-25 Gnt, Llc Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations
DE102016204472A1 (de) * 2016-03-17 2017-09-21 Ursapharm Arzneimittel Gmbh Kit zur kosmetischen Behandlung des Auges und der Haut und Kosmetikum zur Anwendung am Auge und auf der Haut
WO2019123266A1 (en) * 2017-12-20 2019-06-27 Novartis Ag Ophthalmic composition having a prostaglandin and a beta-blocker
BR112021000863A2 (pt) * 2018-05-01 2021-04-13 Jinan Cao Colírios que curam cataratas, presbiopia e
CN109172580B (zh) * 2018-09-06 2021-04-27 中山万汉制药有限公司 包含前列腺素衍生物的组合物以及包含该组合物的眼用液体制剂
CN110200904B (zh) * 2019-05-27 2021-07-23 上海昊海生物科技股份有限公司 一种降眼压缓释滴眼组合物及其制备方法
KR102308566B1 (ko) * 2019-05-28 2021-10-05 서울대학교병원 녹내장 안약의 약물이상반응 진단 키트
WO2020252224A1 (en) * 2019-06-14 2020-12-17 3D Systems, Inc. Polypropylene-based particles for additive manufacturing
CN115989021A (zh) * 2020-06-21 2023-04-18 I.Com医疗有限责任公司 用于治疗和预防高眼压症和青光眼的基于透明质酸的制剂
CN111840225B (zh) * 2020-08-12 2021-09-14 陈丽娜 一种用于治疗青光眼的滴眼剂及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI110483B (fi) * 1999-09-20 2003-02-14 Parker Hannifin Oy Suodatuslaitteisto
WO1998053809A1 (en) * 1997-05-30 1998-12-03 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US6593369B2 (en) * 1997-10-20 2003-07-15 Vivus, Inc. Methods, compositions, and kits for enhancing female sexual desire and responsiveness
BR9906597A (pt) * 1998-07-14 2000-07-18 Alcon Lab Inc Produto de prostaglandina
AU5001199A (en) * 1998-07-21 2000-02-14 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
CH692919A5 (fr) * 1999-01-28 2002-12-13 Trb Chemedica S A Procédé de purification de l'acide hyaluronique à poids moléculaire élevé.
US6395787B1 (en) * 2000-02-08 2002-05-28 Allergan Sales, Inc. Ocular hypotensive lipids
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
EP1547599B1 (en) * 2002-09-09 2017-11-01 Santen Pharmaceutical Co., Ltd. Transparent eye drops containing latanoprost
US20040225014A1 (en) * 2003-02-14 2004-11-11 Sucampo Ag Method for treating ocular hypertension and glaucoma
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
DE602004018990D1 (de) * 2004-05-26 2009-02-26 Bayardo Arturo Jimenez Verfahren zur herstellung einer latanoprost-augenlösung und so hergestellte lösung
US20050276867A1 (en) * 2004-06-09 2005-12-15 Allergan, Inc. Stabilized compositions comprising a therapeutically active agent and an oxidizing preservative
US20060073184A1 (en) * 2004-09-29 2006-04-06 Bausch & Lomb Inc. Viscoelastic composition, methods of use and packaging device with anti-oxidant
WO2006133048A2 (en) * 2005-06-03 2006-12-14 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same
DE102005055275A1 (de) 2005-11-17 2007-05-24 Ursapharm Arzneimittel Gmbh & Co. Kg Phosphatfreie pharmazeutische Zusammensetzung sowie deren Verwendung
WO2008027340A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
WO2008096804A1 (ja) * 2007-02-07 2008-08-14 Teika Pharmaceutical Co., Ltd. ラタノプロスト含有点眼剤
EP1985298A1 (en) * 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins
ITRM20080182A1 (it) * 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.

Also Published As

Publication number Publication date
ES2644218T3 (es) 2017-11-28
RU2011143860A (ru) 2013-06-20
WO2010130462A8 (de) 2011-03-10
KR20120047851A (ko) 2012-05-14
DE102009021372A1 (de) 2010-11-18
WO2010130462A3 (de) 2011-01-27
US20120122976A1 (en) 2012-05-17
WO2010130462A2 (de) 2010-11-18
CN102421425A (zh) 2012-04-18
PT2429507T (pt) 2017-10-30
PL2429507T3 (pl) 2018-01-31
EP2429507B1 (de) 2017-07-19
EP2429507A2 (de) 2012-03-21

Similar Documents

Publication Publication Date Title
MX2011011957A (es) Composicion farmaceutica libre de fosfatos para el tratamiento del glaucoma.
IN2012DN02661A (es)
MX2012003555A (es) Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
MX336038B (es) Composiciones farmaceuticas de liberacion controlada de tapentadol.
JO3297B1 (ar) تركيبات و طرق لتعديل fxr
MX2012003389A (es) Moduladores de gpr40 de pirrolidina.
GB2460597A (en) N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
MY156288A (en) Pharmaceutical formulations containing dopamine receptor ligands.
MX2013010046A (es) Administracion parenteral de tapentadol.
EA033171B1 (ru) Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол
UA101091C2 (ru) Способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой
UA103996C2 (en) Ivabradine hydrobromide
MX339619B (es) Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.
TN2014000060A1 (en) Benzothiazolone compound
IL208325A0 (en) Stabilizing lipis compositions for oral pharmaceutical agents
MX2013003863A (es) Metodo para la preparacion de (3s,3s')4,4'-disulfandilbis(acido 3-aminobutano 1-sulfonico).
WO2012151464A3 (en) Use of radiographic contrast agents for detecting dental caries
MX338405B (es) Formulaciones de 2-iminobiotina y sus usos.
WO2011107921A3 (en) Modified release composition of milnacipran
WO2011138797A3 (en) Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
MY183976A (en) Pharmaceutical composition for oral administration with improved dissolution and/or absorption
MX2011009844A (es) Composicion farmaceutica que comprende alisquireno.
TR201006225A1 (tr) Çift salım sağlayan dekslansoprazol oral tablet bileşimleri
TN2011000018A1 (en) Pharmaceutical formulations containing dopamine receptor ligands